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Spray-Dried Succinylated Soy Protein Microparticles for Oral Ibuprofen
Delivery
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Abstract. The potential value of succinylated soy protein (SPS) as a wall material for the
encapsulation of ibuprofen (IBU), a model hydrophobic drug, by spray-drying was
investigated. A succinylation rate of 93% was obtained for soy protein isolate, with a molar
ratio of 1/1.5 (NH2/succinic anhydride). The solubility proﬁle at 37°C showed that this
chemical modiﬁcation decreased the solubility of the protein below its isoelectric point,
whereas solubility increased in alkaline conditions. Various SPS/IBU ratios (90/10, 80/20, and
60/40) were studied and compared with the same ratio of soy protein isolate (SPI/IBU). High
encapsulation efﬁciency was achieved (91–95%). Microparticles were spherical and between
4 and 8 μm in diameter. The spray-drying of protein/IBU solutions appeared to be beneﬁcial,
as it resulted in an amorphous solid dispersion of IBU within the microparticles, coupled with
an increase in the thermal stability of IBU. In vitro release was evaluated in acidic (pH 1.2 in
the presence of pepsin) and neutral (pH 6.8) conditions similar to those in the gastrointestinal
(GI) tract. IBU was released signiﬁcantly more slowly at pH 1.2, for both proteins. However,
this slowing was particularly marked for SPS, for which rapid (within 2 h) and complete
release was observed at pH 6.8. These results validate the hypothesis that SPS is suitable for
use as a coating material for hydrophobic active pharmaceutical ingredients (APIs) due to its
pH sensitivity, which should delay IBU release in the gastrointestinal tract.
KEY WORDS: plant protein; succinylation; green excipient; microencapsulation; oral route; modiﬁed
release; pH sensitivity.
INTRODUCTION
In recent decades, the pharmaceutical industry has developed
several strategies for the controlled delivery of active pharmaceu-
tical ingredients (APIs), for oral administration in particular, as this
is the favoured route and most widely used in patients. Microen-
capsulation, in particular, has been widely studied, as this method
can be used to generate different dosage forms, such as powders,
tablets, and capsules (1,2).
There is currently very strong demand for new drug
delivery systems (DDSs) suitable for the chosen administra-
tion route and able to deliver APIs to particular sites, to limit
adverse reactions and side effects, and to improve patient
comfort (1). Microencapsulation is a technological strategy
that seems to perform well, particularly not only for APIs
with a short half-life that are rapidly hydrolysed or broken
down by enzymes in vivo but also for APIs with low solubility
or poor permeation characteristics (3,4).
Spray-drying is a well-established method that is already
widely used in the pharmaceutical industry to convert liquid
formulations into dry powders, in cheap, fast, easy, and
scalable one-step processes (5). This technology can also be
used to encapsulate sensitive APIs, to generate relatively
uniform and stable particles with high encapsulation efﬁcien-
cies and without the need for an organic solvent (6).
The choice of encapsulation carrier is one of the key
parameters in the design of delivery systems for APIs based
on spray-drying. Various natural and synthetic polymers are
currently being explored, but the persistent demand for
environmentally friendly excipients has led to intensive
research into natural polymers, such as polysaccharides and
proteins. Plant proteins are cheap and readily available. They
also seem to be highly suitable for medical applications,
thanks to their bio- and cytocompatibility and their biode-
gradability (7,8). Moreover, their surfactant and ﬁlm-forming
properties make them attractive for microencapsulation
applications. Finally, the presence of amino and carboxyl
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groups on protein chains renders them pH responsive, a
feature that is particularly useful for APIs sensitive to gastric
conditions, for which bioavailability may be decreased by
passage through the gut (9), or for those known to have
gastric side effects (10,11).
Soy, wheat, and maize proteins are the most abundant
plant proteins and have been shown to be potentially useful
for medical applications (8). Microspheres of the maize
protein zein have even been formulated as carriers for
anticancer drugs (12).
However, there have been few studies investigating the
potential of plant protein microparticles for oral API delivery
systems and even fewer evaluating the utility of chemical
modiﬁcations to improve their pH sensitivity. Conversely, the
potential of chemical modiﬁcations, such as acylation or
succinylation, to expand the range of functions of plant
proteins has driven research activities, particularly for re-
search into microencapsulation applications (9,13–16).
Succinylation is the addition of succinic acid to protein
amino groups, resulting in the replacement of mostly
positively charged lysine ε-amino groups with carboxyl
groups, which are negatively charged (for a pH range of
about 4 to 10). This modiﬁcation leads to chain unfolding and
a lower isoelectric point (pI), accompanied by a decrease in
solubility below the pI and an increase in solubility above it
(17). This chemical modiﬁcation is used to enhance certain
functional properties of proteins, such as solubility, emulsi-
ﬁcation, and foaming capacity (18). Succinylation is, thus, a
possible method for modifying the pH sensitivity of soy
protein and controlling the release of active ingredients in
gastrointestinal conditions. Furthermore, succinylation is a
Bsoft^ modiﬁcation, and the use of succinic anhydride is
approved by the Codex Alimentarius (19) and this molecule
is considered to be GRAS (generally recognised as safe) by
the FDA (Food and Drug Administration) (20).
The potentialities of succinylated soy proteins under
microparticulate form for oral applications have never been
explored. Succinylation of proteins has demonstrated its
interest in food research to increase food protein emulsify-
ing and foaming properties (21). Succinylated proteins,
namely soy protein (9) and β-lactoglobulin (22,23), have
also been proposed as excipients to design enteric tablets by
direct compression of mixed proteins and active pharma-
ceutical ingredient (API) powders. More recently, their use
for enteric coating of capsules has been studied (24).
However, the inﬂuence of succinylation on (soy) protein
encapsulation properties has never been explored and is the
subject of this study. Encapsulation could permit innovative
formulations, obtained with alternative industrialisable
process (spray-drying), which may be of great interest for
pharmaceutical applications. In a previous study, we have
evaluated the inﬂuence of soy proteins acylation on their
encapsulation and release properties for oral purposes (16).
We here used the same methodology to evaluate
succinylation inﬂuence, with the goal to compare both
chemical modiﬁcations.
The aim of this study was to investigate the microencap-
sulating properties of succinylated soy protein (SPS), com-
paring them with those of soy protein isolate (SPI), and to
determine its suitability for use as a multiparticulate drug
delivery system.
Ibuprofen (IBU) was chosen as the model drug for this
study. Its poor solubility in water and the gastric adverse
effects reported following its oral administration (25) make
this drug a clear candidate for encapsulation and delayed
release.
In the ﬁrst part of the study, SPI was succinylated and the
impact of this modiﬁcation on soy protein solubility was
analysed. Modiﬁed and native proteins were then used for
IBU microencapsulation by spray-drying, with various
protein/IBU ratios. The effects of protein succinylation on
process yield, IBU encapsulation efﬁciency, microparticle
morphology, and size distribution were examined. IBU
encapsulation state was assessed by DRX and thermogravi-
metric analysis (TGA). Finally, in vitro IBU release kinetics
were studied in simulated gastrointestinal conditions (pH 1.2
with pepsin and 6.8, 37°C).
MATERIALS AND METHODS
Materials
SPI (90% pure) was purchased from Solae Belgium NV
(Ieper, Belgium). Ibuprofen (100% pure) was purchased from
BASF Corporation (USA). All other chemicals for protein
modiﬁcation were of analytical grade. NaOH, 37% HCl,
succinic anhydride, acetonitrile (HPLC grade), and pepsin
from porcine gastric mucosa tested according to European
Pharmacopoeia 9.5 (Ph. Eur.) were purchased from Sigma
(Saint-Quentin Fallavier, France).
SPI Characterisation
SPI proximate composition analysis included determina-
tions of moisture, ash, protein, and lipid contents. Moisture
and ash contents were determined according to the standard
methods of the AOAC (26). Ash content was determined
gravimetrically, by incineration at 550°C, and moisture
content was determined by drying samples to a constant
weight at 105°C. Protein content was determined by the
Kjeldahl method (N × 6.25) (27) and lipid content was
determined by conventional Soxhlet extraction with cyclo-
hexane for 6 h. Total carbohydrate content was obtained by
subtracting the sum of moisture, ash, protein, and lipid
contents from the total mass (27). Proximate analysis was
carried out three times for each sample.
The amino acid proﬁle of SPI was determined with a
Biochrom 30-amino acid analyser (Serlabo Technologies,
Entraigues sur la Sorgue, France).
Succinylation of Soy Proteins
The succinylation reaction (Fig. 1) involves the replace-
ment of positively charged lysine ε-amino groups with
negatively charged carboxyl groups through the addition of
succinic anhydride.
Succinylated soy protein isolate (SPS) was prepared as
described by Shilpashree et al. for the succinylation of milk
protein (20). A 200-g 5% w/w protein solution in deionised
water was prepared in a three-necked ﬂask equipped with a
mechanical stirrer and a pH meter. The pH was adjusted to 8–
8.5 with 2 M NaOH. Succinic anhydride was added in three
stages, over a 30-min period, with mechanical stirring
(500 rpm) at room temperature. The molar ratio of NH2-
proteins/succinic anhydride was 1/1.5. The reaction mixture
was then heated at 37°C for 1 h, and pH was maintained at 8–
8.5 by adding 2 M NaOH solution. The solution was then
cooled at room temperature and the pH was lowered to 3–4
by adding 2 M HCl, leading to protein precipitation. The
reaction mixture was centrifuged at 5000×g at 20°C for 20 min
in a 6-16K Sigma Centrifuge (Osteode, Germany). The
supernatant was removed and the precipitate was dissolved
in 100 mL of water. The pH was adjusted to 7 (with 2 M
NaOH solution). The reaction product was lyophilised
(Lyophiliser Alpha 2-4, Christ Martin) and stored at 4°C.
The succinylation rate (SR) was calculated by determin-
ing the number of amine functional groups by the OPA
method (28).
SR %ð Þ ¼ N0−Nsð Þ=N0½   100
where N0 is the number of mmol of amine groups in the
native protein and Ns is the number of mmol of amine groups
in the protein after succinylation.
A succinylation rate of 93% was obtained.
Protein Solubility Profile
Protein solubility proﬁle was determined according as
described by Zheng et al. (29). Protein samples (SPI and SPS)
were mixed with deionised water (3% w/w) and the pH of the
mixture was adjusted to 1.0–10.0 with 4 M NaOH or 4 M HCl.
Each sample was stirred for 1 h at 37°C and centrifuged at
10000×g for 15 min (Sigma Laborzentrifugen, Osterode,
Germany). The soluble protein content in the supernatant
was determined by the Kjeldahl method (in triplicate).
Protein solubility (S) was calculated with the following
formula:
S %ð Þ ¼ 100 protein weight in the supernatant=total protein weight in solution
Microencapsulation Process
Preparation of Protein/Ibuprofen Solutions
Protein/IBU solutions were prepared with different
ratios of SPI/IBU or SPS/IBU: 90/10, 80/20, and 60/40, as
previously described (16). Protein (succinylated or not) was
dissolved in deionised water (8% w/w) at room temperature,
with magnetic stirring. The pH was then adjusted to 8 and the
IBU was gradually added, with magnetic stirring, over a
period of 30 min. The solutions were mechanically stirred at
500 rpm for 30 min and homogenised at high pressure
(50 MPa) with double circulation (APV Systems,
Albertslund, Denmark).
Viscosity of Protein/Ibuprofen Solutions Prior to Spray-Drying
The analysis of apparent viscosity of all solutions was
determined at 25°C with shear stress of 0 and 1 N/m2 for
2 min, using a Rheometer Anton Paar MCR-302 (United
Kingdom) with cone-plate geometry of 6 mm diameter and
0.035 rad angle (30).
Spray-Drying
The solutions (200 mL) were spray-dried in a Mini Spray
dryer B-290 (Büchi, Flawil, Switzerland) under the following
process conditions: inlet air temperature at 120 ± 4°C and
outlet temperature at 74 ± 4°C, drying air ﬂow rate of 470 L/h,
liquid feed ﬂow rate of 0.33 L/h, and 100% aspiration.
Microparticles were collected and stored at 4°C.
Spray-drying yield (%) was calculated as follows:
Spray−drying yield %ð Þ ¼ Mp=MSPþIBU  100
where Mp is the mass of the powder collected and MSP+IBU is
the initial mass of solid content in the solution, including soy
protein (succinylated or not) and IBU.
HPLC Analysis
IBU concentration was determined in an HPLC system
equipped with a reverse-phase column (Phenomenex Gem-
ini® 5 μm C18 110 Å, 250 × 4.6 mm) and a precolumn ﬁlled
with the same phase. This system consisted of a Dionex P680
quaternary pump, a Dionex ASI-100 autosampler, an Ulti-
Mate 3000 thermostat-controlled column compartment, and a
Thermo Scientiﬁc Ultimate 3000 UV-DAD detector. A
wavelength of 222 mm was used for UV detection. The
mobile phase was a 60:40 (w/w) mixture of 0.1 M sodium
acetate (pH 7) and acetonitrile.
Microparticles (10 mg) were dissolved in 50 mL of the
mobile phase and sonicated for 10 min and were then stirred
magnetically for 20 min. All samples were ﬁltered through
Fig. 1. Protein succinylation reactions
CA ﬁlters with 0.45 μm pores and then analysed, in triplicate,
by HPLC.
The amount of IBU in microparticles and for the in vitro
study was determined from ibuprofen calibration curves, as
previously described (16).
Microencapsulation Efficiency and Microencapsulation Rate
Microencapsulation efﬁciency (MEE) and microencap-
sulation rate (MER) were calculated as follows:
MEE ¼ IBUexp=IBUtheo  100
where IBUexp is the amount of ibuprofen in microparticles, as
determined by HPLC, and IBUtheo is the amount of
ibuprofen theoretically introduced in the solutions.
MER ¼ mIBU=mm  100
where mIBU is the estimated mass of ibuprofen in micropar-
ticles, and mm is the mass of the microparticle sample
analysed.
Microparticle Characterisation
Moisture Content
The moisture content of the microparticles was deter-
mined gravimetrically, by oven-drying at 105°C to constant
weight.
Microparticle Size Distribution
The size distribution of the microparticles was deter-
mined by laser diffractometry with a Sirocco 2000 machine
(Malvern Instruments, Worcestershire, UK). A refractive
index of 1.52 was used, with an air dispersion pressure of
4 bars. The volume-based particle diameters (D4,3) and
surface-based particle diameters (D3,2) were calculated as
the mean of three measurements per sample.
Morphology
Microparticles were observed by scanning electron
microscopy (SEM) with a LEO435VP scanning electron
microscope (LEO Electron Microscopy Ltd., Cambridge,
UK) operating at 10 kV. They were deposited on a
conductive double-faced adhesive tape and sputter-coated
with silver.
X-Ray Diffraction
The powder crystallinity of ibuprofen, SPI, SPS,
microparticles, and physical mixtures was assessed by X-
ray powder diffraction (EQUINOX 1000, France) at room
temperature with a Co target at 30 mA and 30 kV in the
5° ≤ 2θ ≤ 40° region, with an angular increment of
0.02° s−1 (31).
Thermogravimetric Analysis
TGA was carried out with an ATG/ETD Q600 machine
from TA Instruments (New Castle, USA), at a linear heating
rate of 10°C/min under air ﬂow, from 20 to 600°C. The
thermal stabilities of ibuprofen, ibuprofen/protein physical
mixtures, and microparticles are presented on TG curves.
In Vitro Release Kinetics
Drug release experiments were performed under sink
conditions in ﬂow-through cells (Sotax EC6), as recom-
mended by the European Pharmacopoeia 9.5 (Ph. Eur.), with
SPI/IBU and SPS/IBU (90/10) microparticles. Simulated
gastrointestinal ﬂuid (SGIF) was used in a closed system
(300 or 100 mL of dissolution medium at pH 1.2 and pH 6.8,
respectively). The dissolution medium was as recommended
by Ph. Eur. The release medium was simulated gastric ﬂuid
(SGF) at pH 1.2 supplemented with 0.32% pepsin (w/v) and
simulated intestinal ﬂuid (SIF) at pH 6.8. The cells were
maintained at 37°C, under a constant ﬂow rate of 8 mL/min.
Drug release was followed by taking 1 mL samples (n = 3) at
predeﬁned time intervals for 2 h. The amount of drug
released at each time point was determined by the previously
described HPLC-UV method.
Statistical Analysis
The experimental data were subjected to statistical
analysis with the MINITAB Release 17 statistical package
(Minitab Inc., USA). A one-way analysis of variance
(ANOVA) with a conﬁdence level of 0.95 and Tukey-
Kramer tests for multiple comparisons were performed.
RESULTS AND DISCUSSION
SPI Composition
As previously reported (16), the SPI used not only
consisted essentially of protein (87.6%) but also contained
0.4% lipids, 5.3% ash, 1.4% carbohydrates, and 5.4% water.
An analysis of SPI amino acid composition revealed a
predominance of two amino acids: glutamic acid (17.8%) and
aspartic acid (11.6%), accounting for the low isoelectric point
of the protein (pI = 5). Lysine levels were also relatively high
(6.3%), and the free amino groups of this amino acid could be
used for chemical modiﬁcations, such as succinylation.
Zhao et al. (2018) reported very similar results for a SPI
containing 18.37–17.59% glutamic acid, 10.45–11.47%
aspartic acid, and 5.16–5.62% lysine (32).
Impact of Succinylation on Soy Protein Solubility
The effect of succinylation on soy protein solubility is
shown in Fig. 2. SPI has a typical bell-shape pH-solubility
proﬁle, with minimum solubility at the isoelectric point.
Succinylation led to a signiﬁcant decrease in solubility at pH
values below the pI. This effect can be explained by the
removal of ammonium groups from lysine residues by
succinylation, leading to the presence of too few hydrophilic
cationic groups to counterbalance hydrophobic protein-
protein interactions and, thus, protein-protein aggregation
(17). Conversely, at pH values above 6 (i.e. above the pKa),
the carboxyl groups of both glutamic and aspartic acids, and
those induced by succinylation, were in their hydrophilic
sodium carboxylate forms, enhancing interactions between
the protein and water and, thus, protein chain unfolding and
solubility (20). As it can be seen on Table I, for similar
protein/IBU ratio, the SPS solutions demonstrated a signiﬁ-
cant higher viscosity than those with SPI (p < 0.05), traducing
higher solubility and protein chain unfolding.
These solubility proﬁles highlight the relevance of the
chosen chemical modiﬁcation, as succinylation greatly de-
creased protein solubility in acidic conditions and maximised
solubility (almost 100%) at pH values above 6.
Protein/IBU solution spray-drying experiments were
performed at pH 8, to maximise the solubility of IBU and
proteins and ensure effective encapsulation.
Impact of Succinylation on Microencapsulation
Process yield, microencapsulation efﬁciency (MEE)
and rate (MER), and microparticle size (Table II) and
morphology (Fig. 3) were determined for spray-dried
microparticles of unloaded SPI and SPS and for SPI/IBU
and SPS/IBU microparticles loaded with various amounts of
IBU (from 90/10 to 60/40 ratios, % w/w).
Microparticles loaded with protein and IBU were
successfully prepared by the spray-drying technique. Spray-
drying yield ranged from 72 to 87% and was higher than
published values for the use of plant proteins for spray-drying
encapsulation (13,15,33,34) and IBU encapsulation (5,35).
MEE values were highly satisfactory, exceeding 80%
for all experiments. However, several signiﬁcant differences
were observed. For a given protein/IBU ratio, MEE was
higher for SPS than for SPI, particularly for high IBU
contents (91.4% and 81.6%, respectively), conﬁrming the
relevance of the chosen chemical modiﬁcation for
optimising IBU encapsulation. This higher encapsulation
efﬁciency can be attributed to the higher solubility of SPS
(at pH 8), enhancing protein chain unfolding, thereby
improving the encapsulation of the IBU molecules.
Conversely, MEE decreased for at high levels of IBU
loading, for both proteins, but this decrease was signiﬁcantly
smaller for SPS microparticles. With SPS, it was possible to
load the microparticles with large amounts of IBU (MER
greater than 36%) with a very high MEE, greater than 91%.
IBU-loaded microparticle moisture content was slightly
lower than reported in many previous studies (30) due to the
hydrophobicity of IBU. It ranged from 2.3 to 3.8%, ensuring
microbiological stability (36).
SEM micrographs (Fig. 3) showed that spray-dried
microparticles had similar morphologies, regardless of the
protein used and the protein/IBU ratio. They were round,
with no ﬁssures or disruption, ensuring that the API was
well-embedded (37). A wrinkled surface may occur accord-
ing to primary drying kinetics of spray-drying process and
feeding solution composition and solid/liquid ratio (38).
Microparticles volume diameter, as measured by laser
granulometry, ranged from 3.5 to 7.6 μm (Table II),
consistent with SEM observations. The aggregates of SPI
microparticles observed on SEM may account for the large
diameters obtained for these microparticles (19.1 μm). In
Fig. 2. Solubility proﬁle of SPI and SPS as a function of the pH of the medium
Table I. Viscosity of Protein/Ibuprofen Solutions Prior to Spray-Drying
Soy protein/ibuprofen (% w/w) SPI SPI 90/10 SPI 80/20 SPI 60/40 SPS SPS 90/10 SPS 80/20 SPS 60/40
Viscosity mPa s 3.2 ± 0.1g 3.7 ± 0.0f 4.2 ± 0.0e 7.2 ± 0.1c 7.4 ± 0.1bc 7.5 ± 0.2b 6.6 ± 0.0d 11.4 ± 0.1a
Superscripts with the same letters (a–g) in the same line were not signiﬁcantly different p > 0.05 (Tukey-Kramer multiple mean comparisons)
SPI soy protein isolate, SPS succinylated soy protein
addition, the microparticles had a trimodal size distribution
(results not shown), with a majority population at about
5 μm. Microparticle size was unaffected by formulation. The
initial solutions had a low viscosity, and the particle sizes
obtained were those expected for a B-290 spray-dryer (13).
Crystalline State of Encapsulated IBU
The crystalline state of encapsulated IBU was assessed
by X-ray powder diffraction (XRD). The XRD patterns of
IBU were compared with those for physical mixtures and
Table II. Properties of Loaded Spray-Dried Microparticles
Soy protein/ibuprofen
(% w/w)
Spray-drying
yield (%)
MEE (%)* MER (%)* Microparticle size Moisture content of
microparticles (%)
(D4,3) μm (D3,2) μm
SPI 80 – – 5.0 ± 0.1c 2.15 ± 0.1 5.1 ± 0.1a
SPS 77 – – 5.3 ± 0.1c 2.01 ± 0.1 3.5 ± 0.4bc
SPI 90/10 82 92.6 ± 9.3ab 9.3 ± 0.9e 3.5 ± 0.2c 1.68 ± 0.1 3.7 ± 0.1b
SPI 80/20 87 84.1 ± 3.6bc 16.8 ± 0.7d 4.4 ± 0.3c 1.71 ± 0.0 2.3 ± 0.1d
SPI 60/40 80 81.6 ± 2.8 c 32.6 ± 1.1b 19.1 ± 2.0a 2.89 ± 0.1 3.2 ± 0.1bc
SPS 90/10 78 95.4 ± 0.6a 9.5 ± 0.1e 4.7 ± 0.1c 1.88 ± 0.0 3.8 ± 0.1b
SPS 80/20 76 92.4 ± 1.0ab 18.5 ± 0.2c 5.0 ± 0.1c 1.95 ± 0.0 3.2 ± 0.1bc
SPS 60/40 72 91.4 ± 0.7abc 36.6 ± 0.3a 7.6 ± 0.1b 2.79 ± 0.1 2.8 ± 0.2cd
Superscripts with the same letters (a–c) in the same column were not signiﬁcantly different p > 0.05 (Tukey-Kramer multiple mean
comparisons)
MEE microencapsulation efﬁciency, MER microencapsulation rate, D4,3 volume-based particle diameters, D3,2 surface-based particle
diameters, SPI soy protein isolate, SPS succinylated soy protein
*Determined by HPLC
Fig. 3. Scanning electron micrographs of microparticles: a SPI microparticles, b SPI 80/20, c SPI 60/40, d SPS, e SPS 80/20, and f SPS 60/40.
X5000 scale bar, 2 μm
microparticles of SPI or SPS with IBU, for each protein/IBU
ratio tested. The XRD patterns of IBU, SPS, and a 90/10 SPS/
IBU physical mixture and microparticles are presented in
Fig. 4. The powder X-ray diffractogram of IBU had sharp
peaks at diffraction angles 2θ = 6°, 16°, 17°, 19°, 20°, and 22°,
demonstrating a typical crystalline pattern (39). SPS powder
was semicrystalline, with only one main peak, whereas SPI
was characterised by two major peaks (40). This change in
XRD pattern suggests that the chemical modiﬁcation led to a
change in conformation. All the characteristic major crystal-
line peaks of IBU were also observed in the physical mixture
but were barely detectable in microparticles, suggesting that
IBU was in an amorphous state in the microparticles. Spray-
drying is known to trigger the formation of amorphous solid
dispersions (41,42), a phenomenon that has been reported for
IBU encapsulation with gelatin (31), acylated soy protein
(16), or HPMCP-HP55 and Kollidon VA 64 (5). This change
in crystalline form would be expected to increase solubility
and, thus, the bioavailability of drugs poorly soluble in water
(43).
Thermal Properties of Encapsulated Ibuprofen
The thermal properties of encapsulated IBU were
studied by thermogravimetric analysis (TGA). The TG mass
loss curves of IBU, SPS, and SPS/IBU 60/40 physical mixtures
and microparticles are presented in Fig. 5. Similar behaviour
was observed for the two proteins and for other protein/IBU
ratios. Ibuprofen degradation occurred at about 170°C, with
complete decomposition at 240°C, due to the evaporation of
IBU (44,45). Protein degradation did not begin until 230°C
for SPI and 250°C for SPS, with maximal mass loss occurring
between 250 and 450°C, as generally observed for plant
proteins (30,34).
The small mass loss observed at about 100°C, for all
curves (except that for IBU), can be attributed to the
evaporation of residual water molecules from the plant
protein (SPS).
A comparison of the curves for physical mixtures and
microparticles demonstrated that encapsulation in SPS by
spray-drying effectively protected the IBU. Indeed, the
thermal degradation of physical mixtures began at 170–
175°C, whereas no degradation was observed until 250°C
for SPS/IBU microparticles, conﬁrming that this microencap-
sulation process prevented the thermal degradation of IBU.
To ensure that thermal treatment did not induce non-volatile
degradation products, we performed HPLC analysis on
ibuprofen loaded microparticles exposed to 200°C for 1 h:
the chromatograms remained unchanged (data not shown),
conﬁrming the IBU protection against thermal degradation
Fig. 4. XRD patterns of ibuprofen, SPS, and the SPS/IBU 90/10 physical mixture and microparticles
Fig. 5. TGA curves of IBU, SPS, and the SPS/IBU 60/40 physical mixture and
microparticles
after encapsulation by spray-drying within soy protein
particles.
Impact of Succinylation on the Release of IBU In Vitro
The kinetics of IBU release in vitro were studied in
simulated gastrointestinal ﬂuids, SGF and SIF, in sink
conditions, for 2 h at 37°C. IBU was chosen as a model
BCS (Biopharmaceutical Classiﬁcation System) class II drug
for this study. Indeed, the absorption of BCS class II drugs
(characterised by low solubility and high permeability) can be
signiﬁcantly improved by optimising the formulation so as to
maintain the class II drug in a soluble state at the absorption
site (46). Moreover, IBU is a good candidate for delayed
release because it is known to have gastric side effects.
We showed, in a previous study, that the pH sensitivity of
SPI can be used to decrease IBU release in acidic conditions
(16). In this study, we investigated whether succinylation
could be used to optimise control over this advantageous
property.
In vitro dissolution studies were performed on IBU-
loaded SPI and SPS microparticles, with IBU contents of 10
to 40% w/w. The dissolution proﬁles of IBU from two IBU-
loaded preparations, SPI 90/10 and SPS 90/10, are presented
in Fig. 6.
In both cases, IBU release kinetics differed considerably
between pH conditions, due to the change in soy protein
solubility with pH. Below the isoelectric point, the conforma-
tion of the protein chains resulted in a dense structure
responsible for lower levels of IBU release in SGF. In these
conditions, the mechanism of IBU release in SGF may
involve a combination of (i) rapid release into the medium
of IBU molecules located at the surface of the microparticles
(burst but limited release); (ii) the diffusion of encapsulated
IBU out of the hydrated microparticles; and (iii) the action of
pepsin, a proteolytic enzyme, accelerating IBU release in a
protein content-dependent manner, by triggering microparti-
cle erosion (9). However, this effect is probably very limited
with soy protein, as pepsin preferentially cleaves the peptide
bonds of aromatic amino acids (histidine, phenylalanine,
tryptophan, and tyrosine) (47), of which there are very few
in SPI. Above the isoelectric point (i.e. in SIF), the protein
microparticles rapidly dissolved, releasing their content.
Soy protein succinylation ampliﬁed this phenomenon,
particularly in acidic conditions. Under simulated gastric
conditions, the release proﬁle of IBU differed signiﬁcantly
(p < 0.05) between SPI and SPS microparticles. A statistical
difference between IBU release from SPI and SPS formula-
tions exists at each time point of the kinetics in acidic pH,
except for the ﬁrst one (t = 0.25 h). IBU release was slower
for SPS, reaching 34% in 2 h, whereas about 50% of the total
IBU content was released over the same time period for SPI.
These ﬁndings are consistent with the solubility proﬁles of the
two proteins (Fig. 2), as the solubility of the modiﬁed protein
is much lower than that of the native protein in acidic
conditions. A difference in particle size may also contribute to
a difference in dissolution performance. Nevertheless, regard-
ing the D(2, 3) values (Table II), the surface exposed was
barely affected and this difference not sufﬁcient to explain the
difference in ibuprofen release.
The replacement of positively charged lysine residues
with negatively charged carboxyl groups decreased both the
isoelectric point of the protein (pI from 4.5 to about 3.5) and
its charge density (48), resulting in a decrease in electrostatic
repulsion between proteins at pH 1.2 and protein unfolding
(23). Consequently, forces acting over short distances, such as
van de Waals attraction and hydrophobic effects, dominated
(9), potentially leading to IBU–SPS interactions, slowing IBU
release. At acidic pH, SPS is practically uncharged (the
succinylation rate is of 93%) and so does IBU whose pKa is
4.54. As a consequence, van der Waals and hydrophobic
interactions are the only potential interactions that can occur
in the dissolution medium and may explain slower IBU
release.
Under simulated intestinal conditions, at pH 6.8, IBU
release was rapid for both formulations, with more than 70%
of the IBU released after 15 min and complete IBU release
after 1 h. The rate of IBU release from SPS was slightly
higher than that from SPI, but this difference was not
statistically signiﬁcant. The amorphisation of encapsulated
IBU, which increased solubility, leading to the rapid degra-
dation of protein microparticles in the release medium, did
not reveal an effect of greater SPS solubility at neutral pH.
However, IBU release from SPS microparticles appeared to
be more even, with a lower standard deviation during the ﬁrst
hour. SPS appears to be a valuable candidate for controlling
and delaying the release of hydrophobic APIs, given the
Fig. 6. Ibuprofen release kinetics with SPI and SPS (at a 90/10 ratio) in simulated gastric ﬂuid
(SGF) at pH 1.2 with pepsin and simulated intestinal ﬂuid at pH 6.8 (SIF)
lower levels of IBU release observed in acidic conditions and
the rapid release of this API at neutral pH.
CONCLUSION
The results presented demonstrate the suitability of SPS
for the encapsulation of hydrophobic APIs by spray-drying,
particularly for delayed-release oral applications.
Succinylation greatly decreased protein solubility at acidic
pH while maximising solubility (almost 100%) at pH values
above 6. Higher encapsulation efﬁciencies were thus obtained
for IBU (higher than 90%), a model hydrophobic drug.
Individual microparticles were observed, even at high IBU
contents (protein/IBU ratio of 60/40). In vitro release kinetics
reﬂected the optimised pH sensitivity of SPS, resulting in
lower levels of IBU release in acidic conditions than were
observed with SPI microparticles. The chemical modiﬁcation
of soy protein did not affect the change in IBU crystalline
state upon spray-drying. An amorphous molecular dispersion
of IBU was obtained, which improved the thermal stability of
the drug (by comparison with IBU alone and with IBU
encapsulated in SPI) and resulted in rapid dissolution at
neutral pH (simulated intestinal ﬂuid), for both proteins. SPS
therefore appears to be a promising material for the
encapsulation of hydrophobic API in a multiparticulate form
for delayed delivery. Such microparticles could be adminis-
tered as a powder or in a capsule form, via the oral route.
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